Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Huth

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology in Drug Development|October 22, 2025
Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy ParticipantsMatthias Hoch, Wendy Weis, Felix Huth, et al.
Pharmaceuticals (Basel, Switzerland)|March 28, 2026
Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast CancerYan Ji, Felix Huth, Craig Wang, et al.
Clinical Pharmacology and Therapeutics|June 20, 2020
Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug LabelingTanay S Samant, Felix Huth, Kenichi Umehara, et al.
Clinical Pharmacology and Therapeutics|November 15, 2017
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical EvaluationsTanay S Samant, Shyeilla Dhuria, Yasong Lu, et al.
Clinical Pharmacokinetics|March 18, 2026
Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy ParticipantsMatthias Hoch, Amanda J Taylor, Felix Huth, et al.
Molecular Pharmaceutics|June 7, 2023
Interlaboratory Variability in the Madin-Darby Canine Kidney Cell ProteomeMatthew D Harwood, Katharina Zettl, Manuel Weinheimer, et al.
Archives of Toxicology|July 18, 2024
Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC)Vlasia Kastrinou-Lampou, Raquel Rodríguez-Pérez, Birk Poller, et al.
Clinical Pharmacokinetics|October 29, 2024
Clinical Pharmacology of Asciminib: A ReviewMatthias Hoch, Felix Huth, Paul William Manley, et al.
Clinical Pharmacology and Therapeutics|September 26, 2023
Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical IndustryRyota Kikuchi, Paresh P Chothe, Xiaoyan Chu, et al.
Drug Metabolism and Pharmacokinetics|January 6, 2026
Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidanceKenichi Umehara, Andrew Harrell, Chandra Prakash, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology in Drug Development|October 22, 2025
Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy ParticipantsMatthias Hoch, Wendy Weis, Felix Huth, et al.
Pharmaceuticals (Basel, Switzerland)|March 28, 2026
Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast CancerYan Ji, Felix Huth, Craig Wang, et al.
Clinical Pharmacology and Therapeutics|June 20, 2020
Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug LabelingTanay S Samant, Felix Huth, Kenichi Umehara, et al.
Clinical Pharmacology and Therapeutics|November 15, 2017
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical EvaluationsTanay S Samant, Shyeilla Dhuria, Yasong Lu, et al.
Clinical Pharmacokinetics|March 18, 2026
Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy ParticipantsMatthias Hoch, Amanda J Taylor, Felix Huth, et al.
Molecular Pharmaceutics|June 7, 2023
Interlaboratory Variability in the Madin-Darby Canine Kidney Cell ProteomeMatthew D Harwood, Katharina Zettl, Manuel Weinheimer, et al.
Archives of Toxicology|July 18, 2024
Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC)Vlasia Kastrinou-Lampou, Raquel Rodríguez-Pérez, Birk Poller, et al.
Clinical Pharmacokinetics|October 29, 2024
Clinical Pharmacology of Asciminib: A ReviewMatthias Hoch, Felix Huth, Paul William Manley, et al.
Clinical Pharmacology and Therapeutics|September 26, 2023
Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical IndustryRyota Kikuchi, Paresh P Chothe, Xiaoyan Chu, et al.
Drug Metabolism and Pharmacokinetics|January 6, 2026
Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidanceKenichi Umehara, Andrew Harrell, Chandra Prakash, et al.
Pageof 5